DLDavid Liao

David Liao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


David Liao has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Vikas Mehta

    Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center Albert Einstein College of Medicine New York New York U.S.A.

    3 shared publications
  • Bradley A. Schiff

    Montefiore Medical Center/Albert Einstein College of Medicine Bronx New York U.S.A.

    2 shared publications
  • Daniel Li

    Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center Albert Einstein College of Medicine New York New York U.S.A.

    2 shared publications
  • Angela Cao

    Department of Otorhinolaryngology–Head and Neck Surgery Albert Einstein School of Medicine/Montefiore Medical Center Bronx New York U.S.A.

    1 shared publication
  • Ankita Naraparaju

    Albert Einstein College of Medicine, Bronx, New York, USA

    1 shared publication
  • Arielle Thal

    Department of Otorhinolaryngology–Head and Neck Surgery, Montefiore Medical Center Albert Einstein College of Medicine New York New York U.S.A.

    1 shared publication

Latest Publications

  • Nonsurgical Interventions for Gender-Affirming Facial Feminization: A Scoping Review

    by Sarah Elhachimi, David Z. Liao, Mingyang Gray, Joshua Rosenberg

    Importance: Systematic review will improve understanding of nonsurgical facial feminization techniques, which are useful alternatives or adjuncts to surgical gender affirmation. Objective: To determine the effectiveness of nonsurgical facial feminization techniques in patients seeking gender-affirming feminization by reviewing the literature for patient-reported, subjective, and objective outcomes of feminization. Evidence Review: A comprehensive database search was conducted through July 28, 2022. A total of 264 titles and abstracts were screened by two independent reviewers in Covidence. Of all, 48 met the inclusion criteria for full-text review, and 20 articles were included in the final data extraction. Findings: The most described nonsurgical facial feminization techniques were neurotoxins, fillers, and hair removal. Techniques were derived from cisgender cosmetic procedures to achieve feminine qualities. The most common study type was expert opinion or literature reviews. There were only two studies that analyzed measurable nonsurgical facial feminization techniques. Conclusions and Relevance: There is a lack of high-quality prospective research and randomized, controlled trials specific to the transgender patient population that evaluate outcomes, patient satisfaction, or complications. Such studies are needed to inform evidence-based practices.


  • Open Access

    What's in a Name? A Cost-Effectiveness Analysis of the Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features' Nomenclature Revision

    by Vikas Mehta, Ankita Naraparaju, David Liao, Louise Davies, Bryan R. Haugen, Peter A. Kopp, Susan J. Mandel, Yuri E. Nikiforov, Douglas S. Ross, Jennifer J. Shin, et al.

    Background: The noninvasive subtype of encapsulated follicular variant of papillary thyroid carcinoma (eFVPTC) has been reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) in 2016 to reflect the indolent behavior and favorable prognosis of this type of tumor. This terminology change has also de-escalated its management approach from cancer treatment to a more conservative treatment strategy befitting a benign thyroid neoplasm. Objective: To characterize the reduced health care costs and improved quality of life (QOL) from management of NIFTP as a nonmalignant tumor compared with the previous management as eFVPTC. Methods: A cost-effectiveness analysis was performed by creating Markov models to simulate two management strategies for NIFTP: (i) de-escalated management of the tumor as NIFTP involving lobectomy with reduced follow-up, (ii) management of the tumor as eFVPTC involving completion thyroidectomy/radioactive iodine ablation for some patients, and follow-up recommended for carcinoma. The model was simulated for 5 and 20 years following diagnosis of NIFTP. Aggregate costs and quality-life years were measured. One-way sensitivity analysis was performed for all variables. Results: Over a five-year simulation period, de-escalated management of NIFTP had a total cost of $12,380.99 per patient while the more aggressive management of the tumor as eFVPTC had a total cost of $16,264.03 per patient (saving $3883.05 over five years). Management of NIFTP provided 5.00 quality-adjusted life years, whereas management as eFVPTC provided 4.97 quality-adjusted life years. Sensitivity analyses showed that management of NIFTP always resulted in lower costs and greater quality-adjusted life years (QALYs) over the sensitivity ranges for individual variables. De-escalated management for NIFTP is expected to produce ∼$6–42 million in cost savings over a five-year period for these patients, and incremental 54–370 QALYs of increased utility in the United States. Conclusion: The degree of cost savings and improved patient utility of de-escalated NIFTP management compared with traditional management was estimated to be $3883.05 and 0.03 QALYs per patient. We demonstrate that these findings persisted in sensitivity analysis to account for variability in recurrence rate, surveillance approaches, and other model inputs. These findings allow for greater understanding of the economic and QOL impact of the NIFTP reclassification.


  • Open Access

    Tracheotomy Outcomes in 64 Ventilated COVID‐19 Patients at a High‐Volume Center in Bronx, NY

    by Yasmina Ahmed, Angela Cao, Arielle Thal, Sharan Shah, Corin Kinkhabwala, David Liao, Daniel Li, Michael Parides, Vikas Mehta, Thomas Ow, et al.

    Objectives/Hypothesis: The COVID‐19 pandemic has resulted in a dramatic increase in the number of patients requiring prolonged mechanical ventilation. Few studies have reported COVID‐19 specific tracheotomy outcomes, and the optimal timing and patient selection criteria for tracheotomy remains undetermined. We delineate our outcomes for tracheotomies performed on COVID‐19 patients during the peak of the pandemic at a major epicenter in the United States.Methods: This is a retrospective observational cohort study. Mortality, ventilation liberation rate, complication rate, and decannulation rate were analyzed.Results: Sixty‐four patients with COVID‐19 underwent tracheotomy between April 1, 2020 and May 19, 2020 at two tertiary care hospitals in Bronx, New York. The average duration of intubation prior to tracheotomy was 20 days ((interquartile range [IQR] 16.5–26.0). The mortality rate was 33% (n = 21), the ventilation liberation rate was 47% (n = 30), the decannulation rate was 28% (n = 18), and the complication rate was 19% (n = 12). Tracheotomies performed by Otolaryngology were associated with significantly improved survival (P < .05) with 60% of patients alive at the conclusion of the study compared to 9%, 12%, and 19% of patients undergoing tracheotomy performed by Critical Care, General Surgery, and Pulmonology, respectively.Conclusions: So far, this is the second largest study describing tracheotomy outcomes in COVID‐19 patients in the United States. Our early outcomes demonstrate successful ventilation liberation and decannulation in COVID‐19 patients. Further inquiry is necessary to determine the optimal timing and identification of patient risk factors predictive of improved survival in COVID‐19 patients undergoing tracheotomy.Level of Evidence: 4—retrospective cohort study Laryngoscope, 131:E1797–E1804, 2021


  • A low-cost phantom for ultrasound-guided thyroid fine-needle aspiration training: face and construct validity

    by David Liao, Vikas Mehta, Eugenie Du, Vafa Tabatabaie, I. Martin Levy, Richard Smith, Marc Gibber


  • The safety and efficacy of open bedside tracheotomy: A retrospective analysis of 1000 patients

    by David Z. Liao, Vikas Mehta, Corin M. Kinkhabwala, Daniel Li, Sarah Palsen, Bradley A. Schiff

    Objectives: To evaluate the safety/efficacy of performing open bedside tracheotomy (OBT) in intensive care unit (ICU) patients and identify predictive factors for outcomes.Methods: This is a retrospective cohort study. We identified 1000 consecutive patients undergoing OBT at a single university hospital starting from August 1, 2007. Complication rate, 30‐day mortality, decannulation rate, time to surgery (TTS) from initial consult, and ICU length of stay were analyzed. Multivariate analysis was performed to identify predictors of complication rate, 30‐day mortality, and decannulation rate.Results: Mean TTS was 1.80 days. Major complication rate was 1%. No intraoperative deaths were caused by tracheotomy although two deaths resulted from late tracheotomy‐related complications. Thirty‐day mortality was 26.6%. The only significant predictor for overall complications was mild chronic hepatitis (OR = 2.355). Predictors for 30‐day mortality included platelet count Laryngoscope, 130:1263–1269, 2020